PARP inhibitor shrinks tumors in pancreatic cancer patients with mutations
(University of Pennsylvania School of Medicine) More than two-thirds of pancreatic cancer patients harboring genetic mutations saw their tumor stop growing or shrink substantially after being switched from intensive chemotherapy to the PARP inhibitor rucaparib as a maintenance therapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Genetics | Pancreas | Pancreatic Cancer | University of Pennsylvania